论文部分内容阅读
目的研究分析基础胰岛素和预混胰岛素控制2型糖尿病血糖疗效及安全性。方法 136例2型糖尿病患者,随机分为预混降糖组和基础降糖组,各68例。预混降糖组给予皮下注射预混胰岛素,基础降糖组给予皮下注射基础胰岛素。治疗4个月后,分别记录并比较两组患者的治疗效果及低血糖发生情况。结果两组患者空腹血糖值均明显下降,其中基础降糖组下降幅度明显大于预混降糖组;且基础降糖组的胰岛素总用量明显低于预混降糖组,差异具有统计学意义(P<0.05)。基础降糖组前2个月和后2个月低血糖发生率均明显低于预混降糖组,差异具有统计学意义(P<0.05)。糖化血红蛋白均有不同程度下降,但两组下降值无明显区别,差异无统计学意义(P>0.05)。结论采用基础胰岛素控制2型糖尿病比使用预混胰岛素安全性高,且控制空腹血糖效果好,值得临床推广使用。
Objective To study the efficacy and safety of basal insulin and premixed insulin in controlling type 2 diabetes mellitus. Methods A total of 136 patients with type 2 diabetes mellitus were randomly divided into pre-mixed hypoglycemic group and hypoglycemic group, with 68 cases in each group. Pre-mixed hypoglycemic group given subcutaneous injection of premixed insulin, basal hypoglycemic group given subcutaneous injection of basal insulin. After 4 months of treatment, the therapeutic effects and the incidence of hypoglycemia in both groups were recorded and compared respectively. Results The fasting blood glucose was significantly decreased in both groups, of which the decrease rate in the basic hypoglycemic group was significantly greater than that in the premixed hypoglycemic group, and the total amount of insulin in the basic hypoglycemic group was significantly lower than that in the premixed hypoglycemic group P <0.05). The incidence of hypoglycemia in the first 2 months and the last 2 months in the hypoglycemic group was significantly lower than that in the premixed hypoglycemic group (P <0.05). Glycosylated hemoglobin decreased in varying degrees, but there was no significant difference between the two groups, the difference was not statistically significant (P> 0.05). Conclusion The basal insulin-controlled type 2 diabetes mellitus is more safe than premixed insulin and has a good effect of controlling fasting blood glucose. It is worthy of clinical promotion.